Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

News SummaryMost relevantAll newsSector newsTweets

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
08/16 Seven charged in U.S. insider trading ring
08/15 ABBOTT LABORATORIES : Sources Sought Notice - Maintenance and Software Support/U..
08/15 ABBOTT LABORATORIES : North West London Pathology and Abbott Partner for Diagnos..
08/15 ABBOTT LABORATORIES : Announces extension of cash tender offer for all outstandi..
08/15 ABBOTT LABORATORIES : North West London Pathology and Abbott Partner for Diagnos..
08/14 ABBOTT LABORATORIES : Announces Extension of Cash Tender Offer for All Outstandi..
08/11 ABBOTT LABORATORIES PAKISTAN : Board of directors meeting of Abbott Laboratories..
08/10 ABBOTT LABORATORIES : ' Trademark Application for "PLEX ID" Filed
08/10 ABBOTT LABORATORIES : "Pod with Spray Nozzle and Method of Use" in Patent Applic..
08/07 Siemens to update medical scanner software to deal with security bugs
More news
News from SeekingAlpha
08/16 GETTING DEFENSIVE : Buying Abbott Laboratories And Dominion Energy
08/15 Abbott Diagnostics lands $252M managed equipment contract in Britain
08/15 JOHNSON & JOHNSON : After Rising 15% This Year, What's Next?
08/14 Mylan Suffers From Jet Lag
08/14 Abbott extends offer to buy Alere convertible preferred to the end of month
Financials ($)
Sales 2017 26 470 M
EBIT 2017 5 762 M
Net income 2017 2 348 M
Debt 2017 14 982 M
Yield 2017 2,16%
P/E ratio 2017 45,77
P/E ratio 2018 27,93
EV / Sales 2017 3,84x
EV / Sales 2018 3,56x
Capitalization 86 542 M
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 55,1 $
Spread / Average Target 11%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.77%357 992
NOVARTIS10.12%219 731
ROCHE HOLDING LTD.5.33%217 452
PFIZER2.71%198 782